

FOI 2649

20/09/24

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1a – How many patients were treated with the following drugs for the following diseases from the start of Apr 2024 to the end of Jun 2024?

Please use the latest available 3 months if April to June is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Response Q1a:

Patients as of 13-09-2024

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab	241	133	63	203	188	164
Apremilast	0			0		
Bimekizumab	7			1	1	
Brodalumab	6					
Certolizumab Pegol	5			28	24	22
Deucravacitinib	0					
Etanercept	1			66	36	107
Guselkumab	65			14		
Infliximab (Remicade)	0	0	0	0	0	0
Infliximab (Biosimilars)	3	47	52	10	7	7
Ixekizumab	107			41	12	
Risankizumab	80	0		1		
Secukinumab	27			90	58	
Tildrakizumab	7					
Ustekinumab	28	69	32	0		
Upadacitinib		9	9	5	4	16
Vedolizumab		45	54			
Filgotinib			0			0
Golimumab			1	26	33	19
Mirikizumab			0			
Ozanimod			0			
Etrasimod			0			

Tofacitinib			4	4	0	4
Baricitinib						42
Rituximab						86
Sarilumab						19
Tocilizumab						31

Q1b – How many patients were treated with Ustekinumab and its biosimilars from the start of Jun 2024 to the end of Aug 2024?

Please use the latest available 3 months if June to August is not available and specify which 3 months has been used.

Response Q1b:

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis
Ustekinumab (Stelara)	28	69	32	0
Ustekinumab (Pyzchiva)	0	0	0	0
Ustekinumab (Uzpruvo)	0	0	0	0
Ustekinumab (Wezenla)	0	0	0	0

Email: Foi.Team@Southerntrust.hscni.net